MRKR Marker Therapeutics, Inc. stock chart & analysis
Conviction 4HealthcareScan · Thu, Nov 19, 2026Marker Therapeutics, Inc. (MRKR) closed at $1.32 (+54.71%) on Nov 19, 2026. Its latest daily candle is a three inside up. Price is above its 50-day and above its 200-day moving average. RSI(14) 68, RS Rating 86, -46.3% from its 52-week high, -11.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why MRKR moved
From the StockSetups movers recaps that covered MRKR, newest first. A recap states what was known that day.
- Close+54.7%
Marker Therapeutics closed up 54.7% at $1.32 on 58.5 million shares, about 19 times its 20-day average of 3.0 million. Market cap is $14.2M. It gapped up 18.4% at the open.
Top Stock Movers Nov 19, 2026: Why LVWR, SEAT, MRKR Surged →
Financials as of Wed, Sep 30, 2026 · quarterly.
MRKR technical analysis
Trend
MRKR's moving averages are mixed — no clean uptrend or downtrend. It closed 27.5% above the 50-day ($1.04) and 1.2% above the 200-day ($1.30). ADX(14) at 20 points to a moderate trend. It meets 4 of 8 trend-template criteria.
Momentum
RSI(14) is 68, in the bullish half of its range. MACD crossed above its signal line on the latest session. Its RS Rating of 86 puts its weighted 12-month performance ahead of about 86% of the US market.
Volume and volatility
Volume on the latest session ran 482.0× its 20-day average. It trades about $4.0M a day on average. ATR(14) is $0.1487, 11.3% of price — its typical daily range. A Bollinger Band squeeze just fired. On-balance volume is trending up.
Key levels
The 52-week range is $0.8101 to $2.46; price is 46.3% below the high and 62.9% above the low. The VWAP anchored at the 52-week high is $1.39, above price.
Performance
MRKR returned +46.7% (1 week), +16.8% (1 month), -5.0% (3 months), -7.7% (6 months), +30.7% (1 year), -11.4% (year to date).
About Marker Therapeutics, Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Pharmaceutical Preparations · Listed 1998 · 5 employees
Recent news
- Marker Therapeutics receives $16.2M Texas grant for therapy By Investing.comInvesting.com Canada · Thu, Nov 19, 2026
- Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO StudyYahoo Finance · Thu, Nov 19, 2026
- Texas awarded cancer grants to 12 projects from 207 applications; Marker received $16.2 million.Stock Titan · Thu, Nov 19, 2026
- MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance · Mon, Nov 16, 2026
- Nine-month loss fell 35% at Marker Therapeutics (MRKR), but its funding runway has a limit.Stock Titan · Mon, Nov 16, 2026
SEC filings
EDGAR filings in MRKR · 3 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.